Determinants of survival after re-resection for recurrent glioblastoma: a meta-analysis - Summary - MDSpire

Determinants of survival after re-resection for recurrent glioblastoma: a meta-analysis

  • By

  • Manuel V. Baby

  • Rithvik M. Narendranath

  • Symriti Kaur-Paneser

  • Daniele S. C. Ramsay

  • Hariharan Subbiah Ponniah

  • Srikar R. Namireddy

  • Ahmed Salih

  • Ahkash Thavarajasingam

  • Daniel Scurtu

  • Andreas Kramer

  • Veit Stöcklein

  • Darius Kalasauskas

  • Dragan Jankovic

  • Florian Ringel

  • Santhosh G. Thavarajasingam

  • January 13, 2026

  • 0 min

Share

Objective:

To identify prognostic factors influencing survival following re-resection of glioblastoma, which may guide treatment decisions.

Key Findings:
  • Repeat resection may be associated with improved survival in recurrent GBM, suggesting a potential treatment avenue.
  • The extent of resection and MGMT promoter methylation status are significant prognostic factors, indicating areas for targeted intervention.
  • Patient factors such as age and Karnofsky Performance Status also influence survival outcomes, highlighting the need for personalized assessments.
Interpretation:

The findings suggest that certain prognostic factors can help identify patients who may benefit from re-resection, supporting more personalized treatment strategies for recurrent glioblastoma and potentially improving patient outcomes.

Limitations:
  • Heterogeneity among included studies may affect the generalizability of results, and many studies did not report IDH status, potentially confounding results.
  • Potential biases in the studies reviewed could impact the reliability of the findings.
Conclusion:

This meta-analysis provides a comprehensive assessment of prognostic factors for survival after re-resection in recurrent glioblastoma, highlighting the need for personalized treatment approaches and further research to validate these findings.

Original Source(s)

Determinants of survival after re-resection for recurrent glioblastoma: a meta-analysis

  • by Manuel V. Baby, Rithvik M. Narendranath, Symriti Kaur-Paneser, Daniele S. C. Ramsay, Hariharan Subbiah Ponniah, Srikar R. Namireddy, Ahmed Salih, Ahkash Thavarajasingam, Daniel Scurtu, Andreas Kramer, Veit Stöcklein, Darius Kalasauskas, Dragan Jankovic, Florian Ringel, Santhosh G. Thavarajasingam

  • January 13, 2026

Related Content

Lactate–Albumin Ratio Tied to TBI Mortality

Admission biomarker showed prognostic value alongside clinical scoring systems in pediatric intensive care

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.

Layered precision suturing vs. traditional double-layer closure at cesarean: a randomized trial of uterine scar healing and maternal outcomes